Detailansicht

Wissensnetz

Person

Carsten Michael Denkert (1969-)

Name	Carsten Michael Denkert
Zeit	1969- (Lebensdaten)
Variante	Carsten Denkert
Weitere Angaben	Humanmediziner
Datensatztyp	Person
GND-Nummer	118129929
Datensatz-ID	118129929
Beteiligt an alle anzeigen GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference—a German expert perspective Characterization of hormone receptor and HER2 status in breast cancer using mass spectrometry imaging Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging Deep learning for fully-automated nuclear pleomorphism scoring in breast cancer Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status Neuroendocrine Differentiation in Conventional Colorectal Adenocarcinomas : Incidental Finding or Prognostic Biomarker? Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry - comparison of three different GPA prognostic scores Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry—Comparison of Three Different GPA Prognostic Scores TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy Post-mastectomy radiotherapy after neoadjuvant chemotherapy in breast cancer: a pooled retrospective analysis of three prospective randomized trials Ioncopy: an R Shiny app to call copy number alterations in targeted NGS data Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69) Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus : Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017) Immunological Mechanisms in Breast Cancer - from Bench to Bedside HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials Impact of Multifocal or Multicentric Disease on Surgery and Locoregional, Distant and Overall Survival of 6,134 Breast Cancer Patients Treated With Neoadjuvant Chemotherapy Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer : a substudy of the neoadjuvant GeparQuinto trial [[Elektronische Ressource]] Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy Identification of biology-based breast cancer types with distinct predictive and prognostic features : role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer Prognosefaktoren im Mammakarzinom und im Ovarialkarzinom unter besonderer Berücksichtigung der Cyclooxygenase-2 Prognosefaktoren im Mammakarzinom und im Ovarialkarzinom unter besonderer Berücksichtigung der Cyclooxygenase-2 Prognosefaktoren im Mammakarzinom und im Ovarialkarzinom unter besonderer Berücksichtigung der Cyclooxygenase-2 Modulation der Expression von integrinen und anderen Adhäsionsmolekülen auf Zellinien humaner kolorektaler Karzinome

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Carsten Michael Denkert (1969-)

GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer

Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference—a German expert perspective

Characterization of hormone receptor and HER2 status in breast cancer using mass spectrometry imaging

Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging

Deep learning for fully-automated nuclear pleomorphism scoring in breast cancer

Practice-Changing Perspectives regarding Systemic Therapy in Early Breast Cancer: Opinions of German Experts regarding the 17th St. Gallen International Consensus Conference

Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial

DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status

Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status

Neuroendocrine Differentiation in Conventional Colorectal Adenocarcinomas : Incidental Finding or Prognostic Biomarker?

Predicting prognosis of breast cancer patients with brain metastases in the BMBC registry - comparison of three different GPA prognostic scores

Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry—Comparison of Three Different GPA Prognostic Scores

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer

Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases

Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy

Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials

Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial

Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy

Post-mastectomy radiotherapy after neoadjuvant chemotherapy in breast cancer: a pooled retrospective analysis of three prospective randomized trials

Ioncopy: an R Shiny app to call copy number alterations in targeted NGS data

Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69)

Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus : Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017)

Immunological Mechanisms in Breast Cancer - from Bench to Bedside

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer

Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials

Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials

Impact of Multifocal or Multicentric Disease on Surgery and Locoregional, Distant and Overall Survival of 6,134 Breast Cancer Patients Treated With Neoadjuvant Chemotherapy

Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer

Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer : a substudy of the neoadjuvant GeparQuinto trial [[Elektronische Ressource]]

Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer

Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy

Identification of biology-based breast cancer types with distinct predictive and prognostic features : role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy

Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer

Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer

Prognosefaktoren im Mammakarzinom und im Ovarialkarzinom unter besonderer Berücksichtigung der Cyclooxygenase-2

Prognosefaktoren im Mammakarzinom und im Ovarialkarzinom unter besonderer Berücksichtigung der Cyclooxygenase-2

Prognosefaktoren im Mammakarzinom und im Ovarialkarzinom unter besonderer Berücksichtigung der Cyclooxygenase-2

Modulation der Expression von integrinen und anderen Adhäsionsmolekülen auf Zellinien humaner kolorektaler Karzinome